Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Relationship between mean CagriSema dose and weight loss in the REDEFINE 1 trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress short oral presentation
Amylin
CagriSema
PHASE 3 (RCT)